wire - news in brief
« BACK
Health - Pharmacology - 11.12.2019
Pharmacology - Health - 09.12.2019
Health - Pharmacology - 09.12.2019
Pharmacology - Health - 06.12.2019
Pharmacology - Health - 05.12.2019
Pharmacology - Health - 02.12.2019
Health - Pharmacology - 02.12.2019
Health - Pharmacology - 02.12.2019 
Improving Tuberculosis Screening in Remote Areas
Every year, 1.5 million people die from tuberculosis (TB) worldwide. Diagnosis and treatment is particularly difficult in remote rural areas.
Pharmacology - Health - 28.11.2019
Pharmacology - Health - 24.11.2019
Pharmacology - 21.11.2019
Pharmacology - Health - 17.11.2019
Pharmacology - Health - 15.11.2019
Pharmacology - Health - 15.11.2019
Pharmacology - Health - 13.11.2019
Pharmacology - Health - 12.11.2019
Health - Pharmacology - 12.11.2019
Pharmacology - Health - 11.11.2019
Pharmacology - Health - 11.11.2019
Pharmacology - Life Sciences - 11.11.2019
Pharmacology - Health - 06.11.2019
Pharmacology - Health - 05.11.2019
Pharmacology - Health - 01.11.2019
Pharmacology - Life Sciences - 30.10.2019
Pharmacology - Health - 30.10.2019
Pharmacology - Health - 24.10.2019
Pharmacology - Business / Economics - 22.10.2019
Pharmacology - Health - 21.10.2019
Health - Pharmacology - 18.10.2019
Chemistry - Pharmacology - 17.10.2019 
Change of perspective
Gerd Folkers was the first head of Critical Thinking ETH (CTETH) and left an indelible mark on the initiative.
Pharmacology - Health - 16.10.2019
Pharmacology - Innovation - 14.10.2019 
A smart speaker helps care for the elderly at home
Two students from EPFL have developed a smart speaker with voice-activation technology that connects patients directly to their loved ones as well as caregivers and emergency services.
Pharmacology - Health - 14.10.2019
Pharmacology - Health - 10.10.2019
Pharmacology - Health - 09.10.2019
Pharmacology - Health - 08.10.2019
Pharmacology - Health - 08.10.2019
Pharmacology - Life Sciences - 05.10.2019
Pharmacology - Health - 02.10.2019
Pharmacology - Health - 01.10.2019
Pharmacology - Health - 30.09.2019
Pharmacology - Health - 30.09.2019
Health - Pharmacology - 30.09.2019
Pharmacology - Health - 30.09.2019
Pharmacology - Health - 30.09.2019
Pharmacology - Health - 29.09.2019
Pharmacology - Health - 28.09.2019
Pharmacology - Health - 27.09.2019
Pharmacology - Health - 27.09.2019
Pharmacology - Health - 23.09.2019
Pharmacology
Results 1 - 50 of 1316.
Novartis Kisqali data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Patients & Caregivers Healthcare Professionals Society & ESG MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results
Patients & Caregivers Healthcare Professionals Society & ESG MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Patients & Caregivers Healthcare Professionals Society & ESG Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more
Patients & Caregivers Healthcare Professionals Society & ESG Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more
Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients
Patients & Caregivers Healthcare Professionals Society & ESG Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell di
Patients & Caregivers Healthcare Professionals Society & ESG Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell di
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy
Patients & Caregivers Healthcare Professionals Society & ESG Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versu
Patients & Caregivers Healthcare Professionals Society & ESG Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versu
Novartis breadth of data at 2019 ASH demonstrates commitment to reimagining medicine in hematology through innovative therapeutic platforms
Patients & Caregivers Healthcare Professionals Society & ESG With more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM
Patients & Caregivers Healthcare Professionals Society & ESG With more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM
Every year, 1.5 million people die from tuberculosis (TB) worldwide. Diagnosis and treatment is particularly difficult in remote rural areas.
Novartis PARAGON-HF analyses suggest Entresto benefit beyond HFrEF
Patients & Caregivers Healthcare Professionals Society & ESG Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compare
Patients & Caregivers Healthcare Professionals Society & ESG Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compare
New Novartis medicine Adakveo (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Patients & Caregivers Healthcare Professionals Society & ESG Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications 1 Adakveo reduced the an
Patients & Caregivers Healthcare Professionals Society & ESG Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications 1 Adakveo reduced the an
Novartis receives positive CHMP opinion for Mayzent (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
Patients & Caregivers Healthcare Professionals Society & ESG If approved, Mayzent (siponimod) will be the first and only oral treatment specifically indicated for patients with active seconda
Patients & Caregivers Healthcare Professionals Society & ESG If approved, Mayzent (siponimod) will be the first and only oral treatment specifically indicated for patients with active seconda
New Novartis PREVENT data show Cosentyx delivers early relief in axial spondyloarthritis
Patients & Caregivers Healthcare Professionals Society & ESG 42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores
Patients & Caregivers Healthcare Professionals Society & ESG 42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores
Sandoz presents real-world data showing effectiveness of Erelzi (etanercept-szzs) in rheumatic disease treatment
Patients & Caregivers Healthcare Professionals Society & ESG Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/AR
Patients & Caregivers Healthcare Professionals Society & ESG Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/AR
Roche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone
Roche today announced data from the phase II NOBILITY study, investigating the safety and efficacy of Gazyva (obinutuzumab) for adults with proliferative lupus nephritis.
Roche today announced data from the phase II NOBILITY study, investigating the safety and efficacy of Gazyva (obinutuzumab) for adults with proliferative lupus nephritis.
Roche’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy
Roche today announced positive data from the pivotal Part 2 of SUNFISH, a study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA).
Roche today announced positive data from the pivotal Part 2 of SUNFISH, a study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA).
Novartis Cosentyx shows encouraging results versus Humira * from first-of-its-kind head-to-head trial in psoriatic arthritis
Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira * Statistically signifi
Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira * Statistically signifi
Novartis announces AVXS-101 intrathecal study update
FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study Adverse events that might be expected from the pre-clinical f
FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study Adverse events that might be expected from the pre-clinical f
Roche’s marketing applications for satralizumab in neuromyelitis optica spectrum disorder accepted for review by EMA and FDA
Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis European Medicines A
Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis European Medicines A
Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma
First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the treatment of the most common form of liver cancer Data will be submitted to
First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the treatment of the most common form of liver cancer Data will be submitted to
Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications
Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control
Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control
Gerd Folkers was the first head of Critical Thinking ETH (CTETH) and left an indelible mark on the initiative.
Two students from EPFL have developed a smart speaker with voice-activation technology that connects patients directly to their loved ones as well as caregivers and emergency services.
Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris 40% of patients with pemphigus vulgaris (PV) achieved sustaine
Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris 40% of patients with pemphigus vulgaris (PV) achieved sustaine
Novartis receives FDA approval for Beovu , offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients
AveXis presents updated STRONG data at WMS demonstrating a higher mean increase in Hammersmith Functional Motor Scale-Expanded (HFMSE) scores among older SMA Type 2 patients following one-time intrathecal administration of AVXS-101
Older patients (= 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follo
Older patients (= 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follo
Novartis positive 52-week PREVENT data confirm Cosentyx efficacy in addressing entire axSpA spectrum
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA) Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously.
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA) Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously.
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized Novartis to establish
Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized Novartis to establish
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the fi
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the fi
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint PALLADIUM is part of Phase III PLATINUM clinical development program, which ev
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint PALLADIUM is part of Phase III PLATINUM clinical development program, which ev
Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa
Efficacy of Alecensa (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study Roche will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detec
Efficacy of Alecensa (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study Roche will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detec
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint , IRIDIUM is largest study in Phase III PLATINUM clinical development p
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint , IRIDIUM is largest study in Phase III PLATINUM clinical development p
FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders
Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vascu
Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vascu
Novartis Kisqali delivers consistently superior overall survival - MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs.
In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs.
Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer
New real-world data from the Flatiron database supports clinical benefits of Alecensa (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival Final PFS and updated data from the pivotal Phase III ALEX study reinforces efficacy of Alecensa in first-line ALK-positive non-small cell lung cancer and shows progression free survival of nearly three years Roche will present new data at the Europea
New real-world data from the Flatiron database supports clinical benefits of Alecensa (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival Final PFS and updated data from the pivotal Phase III ALEX study reinforces efficacy of Alecensa in first-line ALK-positive non-small cell lung cancer and shows progression free survival of nearly three years Roche will present new data at the Europea
Roche’s Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone Data wil
Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone Data wil
Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination of Tecentriq and Avastin was shown to reduce the risk of disease worsening or death by 45% compared with Tecentriq monotherapy Data from the Phase Ib cancer immunotherapy combination study will be presented at the European So
The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination of Tecentriq and Avastin was shown to reduce the risk of disease worsening or death by 45% compared with Tecentriq monotherapy Data from the Phase Ib cancer immunotherapy combination study will be presented at the European So
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medici
First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medici
